PALO ALTO, Calif., Nov. 19, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced that David Cory, President and CEO, will present a corporate update at the 30th Annual Piper Jaffray Healthcare Conference on November 27 at 4:00 PM ET at Lotte NY Palace Hotel in New York City.
A live webcast of the presentation will be available on the Eiger BioPharmaceuticals website at www.eigerbio.com under the "Investors" tab. A replay of the webcast will be available approximately one hour following the completion of the live event.
Eiger will also host one-on-one meetings with investors.
About Eiger
Eiger is a late-stage biopharmaceutical company focused on the accelerated development and commercialization of a pipeline of targeted therapies for rare and ultra-rare diseases. Our lead program is advancing Lonafarnib into a Phase 3, single pivotal trial to treat Hepatitis Delta Virus (HDV) Infection, initiating in 2018. Eiger is preparing an NDA for Lonafarnib to treat Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) with plans to file in 2019. For additional information about Eiger, please visit www.eigerbio.com.
Investors: Ingrid Choong, PhD
Email: [email protected]
Phone: 1-650-619-6115
SOURCE Eiger BioPharmaceuticals, Inc.
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article